Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NVAX News 24 November 2025 - 31 January 2026

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

New York, January 22, 2026, 20:16 EST — Market closed Pfizer shares ended Thursday up 0.8%, closing at $26.10 after climbing Wednesday. The stock stayed comfortably within the mid-$20s, fluctuating between $25.75 and $26.31 during the session. (StockAnalysis) The move came as vaccine makers assessed rapid policy changes in the U.S. under Health Secretary Robert F. Kennedy Jr., a shift now creeping into investor talks and sector bets. “Vaccines will not be a growth area under the current administration,” said Stephen Farrelly, ING’s global pharma and healthcare lead. Pfizer CEO Albert Bourla expressed being “seriously frustrated,” blaming the rhetoric for
23 January 2026
·····
Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus

Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus

New York, Jan 22, 2026, 14:34 EST — Regular session Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10. Timing is crucial. Pfizer is working to stabilize its narrative after the COVID-era tailwind waned, as investors prepare for several patent expirations — the “loss of exclusivity” phase when cheaper generics typically hit sales. The company has warned that the next few years will be rough, with no revenue growth expected before 2029. (Reuters) On the HIV front, GSK announced Pfizer is selling
22 January 2026
······
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

New York, January 21, 2026, 14:11 EST — Regular session Pfizer shares gained roughly 0.8%, hitting $25.73 by Wednesday afternoon. The Health Care Select Sector SPDR ETF climbed around 1.2%, while the S&P 500 tracker SPY edged up about 0.5%. The move is modest, but investors are eager for clearer signals about Pfizer’s 2026 outlook after a rough patch for major drugmakers that benefited from pandemic-driven demand before facing a reset. Pfizer’s guidance continues to highlight cost controls, new product launches, and whether its pipeline can carry more weight. (s206.q4cdn.com) Tuesday brought two deal headlines stirring the market. One cuts
21 January 2026
······
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

New York, January 21, 2026, 05:22 EST — Premarket Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase. (Public) Novavax’s deal is significant as the company looks to pivot its platform toward steadier revenue sources amid a drop in pandemic vaccine sales. Investors are increasingly focused on partnerships that bring upfront payments plus ongoing royalties, moving away from relying solely on seasonal demand surges. Pfizer is zeroing in on Matrix‑M, an adjuvant that amplifies the immune
21 January 2026
······
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

New York, January 20, 2026, 14:46 EST — During the regular session Pfizer (PFE) shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount,
20 January 2026
······
Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot

Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot

NEW YORK, January 3, 2026, 05:15 ET — Market closed Novavax Inc (NVAX.O) shares rose 6.1% on Friday to close at $7.13, outperforming in a mixed U.S. session as traders latched onto fresh signs of overseas demand for its updated COVID-19 shot. The stock traded about 38% below its 52-week high of $11.55 set on Jan. 7 last year, according to MarketWatch data. MarketWatch The move matters because it ties the stock to a concrete, near-term distribution window in a government-backed program. Singapore’s Communicable Diseases Agency said the JN.1 Novavax/Nuvaxovid vaccine will be offered at selected general practitioner clinics under
3 January 2026
···
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Data and news current as of 7 December 2025. NVAX stock price now: where Novavax stands in December 2025 Novavax, Inc. (NASDAQ: NVAX) closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value of around $1.1 billion.Novavax Investor Relations+1 Over the last year, NVAX has slipped roughly 20%, according to data from Investing.com and other market trackers.Investing.com+1 That’s modest compared with its longer-term collapse: Simply Wall St calculates that Novavax shares are down about 94% over the past five years, even after a flurry of recent milestones.Simply Wall St+1 Key trading stats as
7 December 2025
·····
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

All figures current as of the U.S. market close on Friday, November 21, 2025. NVAX will next trade when markets reopen on Monday, November 24, 2025. Quick snapshot for NVAX heading into November 24, 2025 Novavax stock price today: where NVAX stands Going into Monday, November 24, 2025, Novavax shares are coming off a choppy stretch. In other words, NVAX is trading like a classic high‑beta biotech: small‑cap, volatile, and highly sensitive to news about regulation, partnerships and activist investors. Latest Novavax news investors need to know 1. Q3 2025 earnings: revenue beat, but losses widen and profitability delayed On
24 November 2025
····

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:46 AM EST Sensex and Nifty Bounce Back Amid IT Sector Weakness, Eyes on US-India Trade Deal February 7, 2026, 12:46 AM EST. India's Sensex rose 0.3% to 83,580.40 and Nifty gained 0.2% to 25,693.7 on Friday, recovering from early losses. The Nifty IT index dropped 1.5%, extending a weekly fall of 5%, pressured by a global tech sell-off linked to rising AI spending and competition. Foreign investors bought equities worth ₹1,951 crore, while domestic institutions sold ₹1,265 crore. The market is cautiously awaiting details of the US-India
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop